HAMBURG, Germany, Oct. 21, 2024 /PRNewswire/ -- Mediso is unveiling its new AnyScan® TRIO SPECT/CT, TheraMAX* scanner at the annual meeting of European Association of Nuclear Medicine (EANM).
The new TheraMAX is specifically designed for serving the clinical needs of theranostic imaging. It features detectors and collimators developed for Targeted Radionuclide Therapies carried out with radioisotopes emitting not only alpha and beta particles, but high and ultra-high energy gamma photons like 177Lu, 212Pb, 131I, 225Ac and beyond.
The TheraMAX is equipped with three, large surface detectors (up to 5x larger than 12-detector CZT systems) surrounding the patients completely (360°). The 15.9mm thick NaI crystals ensure improved sensitivity for high energy photons, while the high-density sensor arrangement (123 PMT per detector head) allows high spatial resolution leading to PET-like image quality in all NM applications.
The 300% sensitivity gain compared to conventional dual-detector systems enables whole body 225Ac SPECT/CT in theranostic imaging, while this extreme total system response also allowing ultra-fast quantitative total-body SPECT/CT scans with 99mTc and LEHR-HS collimator. Moreover, novel multi-pinhole technology combined with Triple-NaI-Detectors provide outstanding performance for cardiology and neurology.
The integrated CT offers three performance levels: low-dose diagnostic scans, ultra-low dose protocol for attenuation and scatter correction and even "Zero-Dose" imaging with AI-powered SyCT** (Synthetic CT).
The first global site for the TheraMAX is the University Hospital Regensburg, Germany. Following a recent installation, Professor Dr. Dirk Hellwig, the head of the Department of Nuclear Medicine said "the new scanner will boost our diagnostic and theranostic workflow, leading to better patient care and it also opens new possibilities in clinical research".
"With the development of the new TheraMAX, we extended the imaging capabilities of nuclear medicine departments by improving the diagnostic confidence of SPECT/CT examinations close to PET/CT" said Istvan Bagaméry, Managing Director of Mediso Ltd. "The TheraMAX transforms the clinical routine also with ultra-fast quantitative total-body scans."
About Mediso
Mediso is a leading manufacturer of molecular imaging techniques to the health care and medical research institutions of the world.
Mediso has a complete profile of imaging research, system development, manufacturing, selling and servicing of multi-modality imaging devices. With over 35-years of expertise, 1400 clinical and 350 preclinical systems installed in over 100 countries, Mediso offers complete solutions from imaging devices to evaluation and quantification software.
*TheraMAX is the configuration name of AnyScan TRIO SPECT/CT with MAX/123-15.9 detector
**Regulatory approval pending
Contact:
info@mediso.com
https://mediso.com/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Mediso introduces true theranostic TheraMAX SPECT/CT
New data on OPTIMASH® F200 and OPTIMASH® AX highlights significant oil yield increase and low-carbon market potential
NEW YORK, Oct. 21, 2024 /PRNewswire/ -- IFF (NYSE:IFF), an industry leader in food, beverage, health, biosciences, and scent, today announced the launch of its OPTIMASH® F200 and OPTIMASH® AX enzyme solutions in combination to maximize corn oil recovery at fuel ethanol plants. New IFF in-plant data shows that this combination can deliver up to 15 percent additional corn oil recovery, helping to meet the growing demand in the biodiesel, renewable diesel, and animal feed industries. Additionally, IFF has developed a proprietary oil mapping calculator to help ethanol producers optimize dosing for maximum recovery. These solutions also enable ethanol producers to sell ethanol into low-carbon intensity (low-CI) markets.
"Every ethanol plant has unique requirements for maximizing value," said Dawn Overby, North America marketing director, Grain Processing, IFF. "By working side-by-side with ethanol producers to offer an optimized combination of OPTIMASH® F200 and OPTIMASH® AX, it can make all the difference to their bottom line. Our expert team is on-hand every step of the way to help them get the most out of their plants — both from a corn oil recovery and low-CI ethanol point of view."
Increasing distillers corn oil (DCO) yield is crucial for extracting the highest value from corn. In the U.S., the average recovery rate is only 50-60 percent of the theoretical yield due to the extremely complex interactions between starch, fiber and protein in corn cell walls, preventing oil release. Without disrupting these interactions, a significant fraction of oil remains unrecovered and lost to the wet cake.
Improving corn oil and low-CI ethanol yields
New in-plant data shows that using OPTIMASH® AX alongside OPTIMASH® F200 directs more oil into thin stillage, increasing the potential for more oil recovery. The combination of both enzyme solutions has been found to boost corn oil yield by 15.7 percent, from 0.89 lb/bu to 1.03 lb/bu.
This enzyme duo also allows ethanol producers to enter low-CI markets by breaking down corn kernel fiber into glucose, which yeast then converts to ethanol. This process results in a lower CI score compared to ethanol from starch, generating increased revenue as a D3 RIN renewable biofuel and potentially qualifying for substantial tax credits. This ethanol is also more valuable for state programs such as the California Low Carbon Fuel Standard.
Optimizing plant efficiencies with technical support
IFF offers comprehensive technical support to ethanol producers from trial stage and beyond. This service includes baseline and trial oil mapping, as well as data analyses to guide custom dosing recommendations for OPTIMASH® F200 and OPTIMASH® AX, increasing oil recovery without affecting downstream processability. IFF experts also collaborate with individual plants to help reduce energy consumption through fiber dewatering enabled by these enzyme solutions.
OPTIMASH® F200 and OPTIMASH® AX are now available across the U.S. For more information, visit here.
###
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, X (Twitter) , Facebook, Instagram, and LinkedIn.
©2024 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with â„¢, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
Contact:
Missy Abbott
Global Communications Leader – Grain Processing
+1-314-6014912
missy.abbott@iff.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
IFF Unveils OPTIMASH® Enzyme Solutions to Boost Corn Oil Recovery by 15 Percent
